chenodeoxycholic acid

PreclinicalSmall molecule

chenodeoxycholic acid is one of 2 small molecule programs targeting Cerebrotendinous Xanthomatosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebrotendinous XanthomatosisActive, not recruiting

Cerebrotendinous XanthomatosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Cerebrotendinous Xanthomatosis

#DrugCompanyPhaseTrials

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

chenodeoxycholic acid

LLeadiant Biosciences, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebrotendinous Xanthomatosis3 trials

Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

Completed·LLeadiant Biosciences, Inc.··NCT05499026·28 enrolled

A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)

Withdrawn·LLeadiant Biosciences, Inc.·Phase 3·NCT06260748

Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

Unknown status·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004346·5 enrolled

Gastric3 trials

Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Completed·HHvidovre University Hospital·Phase 4·NCT02876484·12 enrolled

Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Completed·HHvidovre University Hospital·Phase 4·NCT02340247·11 enrolled

Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass

Completed·HHvidovre University Hospital·Phase 4·NCT02952963·8 enrolled

GLP-11 trial

Effect of Bile Acids on GLP-1 Secretion

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT01666223·20 enrolled

Humans1 trial

Cholestanol in Humans

Withdrawn·UUS Department of Veterans Affairs·N/A·NCT00018694

Peroxisomal Disorders1 trial

Study of Bile Acids in Patients With Peroxisomal Disorders

Terminated·UUniversity of Cincinnati·N/A·NCT00004442·25 enrolled

3 more indications

MPA1 trial

Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT06180057·24 enrolled

Cholecystectomy1 trial

Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

Completed·ZZealand University Hospital·Phase 4·NCT03168555·23 enrolled

Metabolism1 trial

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT00465751·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for chenodeoxycholic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chenodeoxycholic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chenodeoxycholic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leadiant Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLeadiant Biosciences, Inc.

chenodeoxycholic acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebrotendinous Xanthomatosis3 trials

Gastric3 trials

GLP-11 trial

Humans1 trial

Peroxisomal Disorders1 trial

MPA1 trial

Cholecystectomy1 trial

Metabolism1 trial

References

Drug Info

Quick Facts

Related News